StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RPRXBullishAnalyst Target Updateanalyst
Medium materiality5/10

TD Cowen Raises Royalty Pharma Price Target to $80

Nov 18, 2026, 1:12 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The target increase and stated growth rationale are bullish, but the signal rests on a single analyst opinion.

AI summary

What happened, with direct paths to the underlying reporting

TD Cowen raised its RPRX target to $80, about 16% above the posted price of $68.76, citing growth and pipeline upside.

  • Target raised to $80
  • About 16% above posted price

Key facts

  1. 01

    Target: $80

  2. 02

    Posted price: $68.76

  3. 03

    Analyst firm: TD Cowen

  4. 04

    Analyst: Steve Scala

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.